ARPO Aerpio Pharmaceuticals Inc.

0.63
+0.01  (+2%)
Previous Close 0.62
Open 0.62
Price To Book 0.56
Market Cap 25,570,443
Shares 40,588,004
Volume 63,951
Short Ratio
Av. Daily Volume 98,489

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b screening underway - May 14, 2019. Data due 1H 2020.
AKB-4924 (GB004)
Ulcerative Colitis
Phase 2 data released March 18, 2019 did not meet primary endpoint.
AKB-9778 - TIME 2B
Non-Proliferative Diabetic Retinopathy
Phase 1b trial initiation announced June 10, 2019 with data due by end of 2019.
AKB-9778
Primary open-angle glaucoma (POAG)

Latest News

  1. Cincinnati stocks hammered as Dow suffers fourth-biggest drop
  2. Aerpio Reports Second Quarter 2019 Financial Results and Provides Business Update
  3. This Cincinnati stock gained 457% in the first half of 2019: SLIDESHOW
  4. Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
  5. Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks
  6. Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update
  7. Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
  8. Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma
  9. Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock?
  10. Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
  11. Greater Cincinnati pharma firm’s stock plummets
  12. Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
  13. Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018
  14. Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  15. Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019
  16. Aerpio (ARPO) Jumps: Stock Rises 7.8%
  17. Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
  18. Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever
  19. Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth